Gene & Cell Therapy and Rare Diseases’ Research
We conduct extensive research into the rapidly evolving gene and cell therapy and rare diseases arena to empower clients to win. Our strategic insights identify key players and developments, tailored to support BioPharma partners across R&D, clinical, regulatory, and commercial endeavors.
The gene and cell therapy space has advanced rapidly, with new assets targeting therapeutic areas such as oncology, immunology, cardiovascular, CNS, and rare diseases. With multiple companies active and new approvals happening, it’s critical to get strategic insights, whether you are a BioPharma company or investor.
Our services include (amongst others):
For BioPharma clients:
- Market and competitor insights on R&D, clinical development and commercial activities
- Extensive congress coverage, supporting brand owners with up-to-date intelligence
- Landscape analysis strengthened by expert interviews
- BD&L support
For Investors:
- Due diligence research
- New opportunity identification
- Access to experts’ opinion through a combination of in-house expertise and conduct of bespoke interviews
We also invite you to join our LinkedIn Gene, Cell and RNA Therapy Strategy Network group – a hub for networking and information.
Want to better understand and succeed in this complex space? Let’s connect!
Reach out to info@lqventures.com to learn more about our strategic consulting and research capabilities.
October 24, 2025
Public Health Today—October 24, 2025
October 24, 2025
Public Health Video Recap—October 24, 2025
October 24, 2025
Respiratory Today—October 24, 2025
October 24, 2025
Vaccines Today—October 24, 2025
October 24, 2025
Lucid Diligence Brief: Electra Therapeutics $183M Series C
October 23, 2025
Cardiovascular Video Recap—October 23, 2025
October 23, 2025
Lucid Diligence Brief: Takeda and Innovent global oncology partnership
October 23, 2025
Rare Disease Video Recap—October 23rd 2025
October 23, 2025
Cardiovascular Today—October 23, 2025
October 23, 2025
Rare Disease Today—October 23, 2025
October 23, 2025
Cell and Gene Therapy Today—October 23, 2025
October 22, 2025